Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis.

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Abstract Text:

The relative efficacy of fluocinonide and betamethasone benzoate gels in treating the symptoms of psoriasis was evaluated in 335 patients, of whom 263 were analyzable. By means of a paired comparison design in which both drugs were examined simultaneously in the same patient, many potential sources of variation were eliminated. In addition, the analysis took into account the difficulties of pooling results in a multicenter trial. Imposing a rigorous grouping structure on the results from individual clinics minimized differences between clinics and demonstrated consistently high, statistically significant results in favor of fluocinodine gel even when several different statistical approaches were used. Local adverse reactions related to drugs were experienced by few patients.

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Publishing Authors By Initials

For similar skin and connective tissue diseases: skin diseases: skin diseases, papulosquamous: psoriasis research abstracts see: skin and connective tissue diseases: skin diseases: skin diseases, papulosquamous: psoriasis research

PUBMED ID PMID:

MEDLINE DATE:

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Archives of dermatology

VOLUME: 112

Page Numbers: 1729-33

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Dec

YEAR: 1976

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Keywords Mesh Terms:

KEYWORDS: Psoriasis

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Information

Substance Name: Fluocinolone Acetonide

Registry Number: 67-73-2

Grant and Affiliation Information for Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Multicenter trial analysis Fluocinonide and betamethasone gel in psoriasis Related Publications

• Acquired localized hypertrichosis.
• An evaluation of well child clinics in the province of Manitoba.
• Basal cell epithelioma of the palm.
• Clinical application of somatosensory amplification in psychosomatic medicine.
• Construction and architecture of a small animal clinic.
• Does science education need the history of science?
• Health supervision of young children in Manitoba.
• Lichen striatus with nail dystrophy.
• MUC2 is a molecular marker for pseudomyxoma peritonei.
• Melanoacanthoma of the lip.
• Motion of a DNA sliding clamp observed by single molecule fluorescence spectroscopy.
• Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis.
• Pseudo-ophiasis and sickle cell anemia.
• Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
• RECENT ADVANCES IN DERMATOLOGY.
• Restoration of the thumb by transplantation, plastic repair, and prosthesis.
• Rickets: Canada: 1968.
• Terrorism, trauma, and mass casualty triage: how might we solve the latest mind-body problem?
• The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.
• Ulcerative sarcoidosis.
• Urticaria and angioedema.
• What affects time to care in emergency room appendicitis patients?
• [In Process Citation]
• [In Process Citation]
• [In Process Citation]
• [In Process Citation]